Alector Q1 net loss $40.5M ($0.41/sh); INFRONT-3 data on track for Q4 2025

Alector, Inc.

2025-Q1 EPS reported -$0.41 revenue$3,700,000

Net loss of $40.5M ($0.41/sh) vs $36.1M ($0.38/sh) in Q1 2024; collaboration revenue $3.7M (down from $15.9M).
Cash, cash equivalents, and investments total $354.6M as of March 31, 2025; runway extended into second half of 2027.
Topline INFRONT-3 Phase 3 data for latozinemab in FTD-GRN expected in Q4 2025; enrollment complete in PROGRESS-AD Phase 2 for AL101.
Giacomo Salvadore appointed Chief Medical Officer; 2025 guidance reiterated: R&D $175-185M, G&A $55-65M, collab rev $5-15M.
Advancing preclinical Alector Brain Carrier programs including anti-amyloid beta antibody and GCase enzyme replacement therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.